Redwood Pharma enters into agreement with CRO for clinical trial

Redwood Pharma AB (publ) has contracted the Swiss contract research organization (CRO) CROss Alliance® for the management of a clinical phase II trial in patients with chronic dry eye disease. The clinical trial will be performed in Europe where CROss Alliance is well-established and has earlier successfully executed several studies within ophthalmology.

The agreement with Cross Alliance represents an important step in the development of RP101, Redwood Pharma’s new drug candidate for the treatment of dry eye disease in postmenopausal women. After a thorough selection process, the Company has chosen Cross Alliance, which is a firm with significant experience in clinical trials within ophthalmology, and more specifically, dry eye disease.

Martin Vidaeus, CEO Redwood Pharma states: ”We have chosen Cross Alliance based on their successful track record within dry eye disease. Cross Alliance has well-documented experience in managing studies, which have served as the basis for successful deals for development firms such as Redwood Pharma. We are pleased to have Cross Alliance as our partner in this decisive study of our lead project RP101.”

The study will be performed at a small number of select clinics across a number of European countries. The study will include approximately 100 patients, all women with moderate to severe dry eye disease. The study will evaluate safety, as well as efficacy, after a three-month treatment. The Principal Investigator for the study will be Prof. Gerhard Garhöfer at the Medical University of Vienna.

For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29

This information is information that Redwood Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, September 1, 2017.
About Redwood Pharma AB
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.

Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit:

About CROss Alliance®
CROss Alliance® is the commercial brand name for CROSS Research SA and CROSS Metrics SA, a private group of Swiss Contract Research Organizations (CROs) active in the field of clinical drug development for more than 20 years.

CROss Alliance® work is performed in full compliance with GCP procedures, as confirmed by local Authorities (Canton Ticino) and Swiss Confederation Health Authority (Swissmedic) as well as several Sponsor audits and regulatory ispections carried out by foreign Competent Authorities.

CROSS Research SA performs phase I studies in its own facility located close to Lugano (CH) while coordinates and manages Phase I – III trials in European clinical sites with the requested competence for each project. CROSS Metrics SA is completely devoted to Data Management, Statistics and PK activities.

Since 1996 CROss Alliance® companies have performed more than 400 clinical studies and delivered valuable data, often used for regulatory purposes all over the world, to more than 100 Sponsors.